01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Bulk pharmaceutical chemicals and fine chemicals for use in the manufacture of pharmaceuticals; chemicals and chemical preparations for use in the manufacture of pharmaceuticals. Pharmaceuticals; medical preparations; Pharmaceutical preparations; medicines; dietetic substances adapted for medical use; dietetic foods adapted for medical purposes; nutritional additives for medical purposes; vitamin preparations; preparations of trace elements for human and animal use; mineral food supplements; bacterial preparations for medical use. Surgical, medical, dental and veterinary apparatus and instruments; Test equipment for medical use; Diagnostic, examination, and monitoring equipment. Research services in the field of pharmaceuticals. Consulting services in the field of pharmaceuticals; research services in the field of human pharmaceuticals; medical services; information and consultations on medical and/or pharmaceutical topics; Medical analysis services; Medical testing.
The present invention relates to an adduct of palbociclib, a method of preparing the preparing the same, and a pharmaceutical composition comprising the same. More particularly, the invention provides a crystalline form of palbociclib, a method of preparing the same, as well as a pharmaceutical composition comprising the same.
The invention refers to a dosage form comprising a carrier with at least two sections adjoining each other integrally by a linearly solid joint, at least one sections provides at least one active pharmaceutical ingredient (API) and/or pharmaceutically acceptable excipient and/or drug product formulation. Further the invention concerns to a method for manufacturing the dosage form of the before kind. The inventive idea is characterized by manufacturing at least the solid joint by way of a generative manufacturing method. This technique enables to design the solid joint with a maximum degree of freedom in view of shape, size, material to name a few and to provide basis for functionality.
The invention refers to a method for manufacturing a dosage form by additive manufacturing and to a dosage form comprising at least one active pharmaceutical ingredient (API) and/or pharmaceutically acceptable excipient and/or drug product formulation manufactured by an additive manufacturing process. Further the invention concerns to a device for manufacturing a dosage form comprising a nozzle head suitable for implementing in an additive manufacturing system. The inventive idea is directed of using at least one mass flow comprising a liquid and at least one mass flow containing a solid powder being mixed in a carrier gas or carrier liquid,of which at least one mass flow contains at least one active pharmaceutical ingredient (API) and/or pharmaceutically acceptable excipient and/or drug product formulation. The at least two mass flows are mixed completely before depositing said mixture in form of a self-curing material layer onto a working plane in layers for forming said dosage form.
The present invention relates to calcium salts of (S)-2-(diphenylacetyl)-1, 2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid in crystalline form and to a process for producing calcium salts of (S)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid in crystalline form. Further, the present invention relates to a composition comprising a crystalline calcium salt of (S)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid and to a dosage form containing the composition of the invention.
The present invention relates to tapentadol phosphate in crystalline form and to a process for producing tapentadol phosphate in crystalline form. Further,the present invention relates to a composition comprising crystalline tapentadol phosphate and to a dosage form containing the composition of the invention.
C07C 215/54 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
9.
PROCESS FOR PREPARING QUINOLIN-2-YL-PHENYLAMINE DERIVATIVES AND THEIR SALTS
The present invention relates (i) to a process for the preparation of quinolin-2-yl-phenylamine derivatives of formula (I) without a metal catalyst, and (ii) to soluble mineral acid or sulfonic acid salts of (8-chloro-quinolin-2-yl)-(4-trifluoromethoxyphenyl)-amine.
The present invention relates to a novel method for preparing monomethyl fumarate, which can preferably be used in the treatment and/or prevention of systemic diseases, autoimmune diseases, inflammatory diseases such as multiple sclerosis and psoriasis. Further, the present invention relates to the use of specific compounds as intermediates in the process for preparing a monomethyl fumarate prodrug.
C07C 67/08 - Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
C07C 67/11 - Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with ester groups or with a carbon-halogen bond being mineral ester groups
C07C 67/333 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisationPreparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by change of size of the carbon skeleton
C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
C07D 207/404 - 2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
C07C 69/90 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with esterified hydroxyl and carboxyl groups
The present invention relates to a crystalline form of abemaciclib, a method of preparing the same, as well as a pharmaceutical composition comprising the same.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
The present invention relates to novel derivatives, preferably prodrugs, of licofelone suitable as a medicament, preferably in the treatment and/or prevention of systemic diseases, autoimmune diseases or inflammatory diseases. Further, the invention relates to a pharmaceutical composition comprising the novel compounds. The compounds are of formula (I) where L is a linear organic residue comprising 2 to 30 carbon atoms, and R is -OH or -OOCR', wherein -OOCR' is a carboxylate group which is hydrolyzable during small intestinal transit. Formula (I)
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
The present invention relates to novel compounds, e.g. for use as a medicament. In particular, the present invention relates to novel derivatives of certain nonsteroidal anti-inflammatory drugs, suitable as a medicament, preferably in the treatment and/or prevention of systemic diseases, autoimmune diseases, and/or inflammatory diseases, for example osteoarthritis, rheumatoid arthritis, multiple sclerosis and psoriasis. Further, the invention relates to a pharmaceutical composition comprising the novel compounds.
A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
15.
PROCESSES FOR PREPARING SOLID STATE FORMS OF DOLUTEGRAVIR SODIUM
A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
C07H 19/10 - Pyrimidine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids
C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07H 1/00 - Processes for the preparation of sugar derivatives
A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
The invention relates to a new crystalline form of palbociclib of Formula (I) and acetic acid adducts of palbociclib, methods of preparing the same, as well as pharmaceutical compositions comprising the same. (formula I)
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressing; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
The present invention relates to filgotinib hydrochloride acid addition salt, its polymorphs, a method of preparing the same as well as a pharmaceutical composition comprising the same.
A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
The present invention relates to filgotinib sulfonic acid addition salts, their polymorphs, a method of preparing the same as well as a pharmaceutical composition comprising the same.
A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
The present invention relates to novel compounds, e.g. for use as a medicament. In particular, the present invention relates to novel prodrugs of monomethyl fumarate (MMF) suitable as a medicament, preferably in the treatment and/or prevention of systemic diseases, autoimmune diseases, inflammatory diseases, for example multiple sclerosis and psoriasis.
C07C 229/22 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
A61K 9/00 - Medicinal preparations characterised by special physical form
The present invention relates to co-crystals of ibrutinib with carboxylic acids, a pharmaceutical composition comprising the same as well as a method of preparing the same.
The present invention relates to a solid pharmaceutical composition comprising amorphous sofosbuvir and at least one phospholipid, preferably in the form of a tablet. The patent also relates to a process for preparing such compositions and to the use of the solid pharmaceutical composition for the treatment of hepatitis C virus infections.
The present invention relates to a premix comprising vemurafenib, in particular vemurafenib hydrochloride, and hydroxypropyl methyl cellulose acetate succinate, which is herein referred to as HPMC-AS in a specific weight ratio and to oral dosage forms comprising said premix. Further, the invention relates to a process for producing said premix comprising vemurafenib hydrochloride and HPMC-AS and to the corresponding process of producing an oral dosage form containing the premix of the invention.
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
26.
COMPOSITION COMPRISING VEMURAFENIB AND CATIONIC COPOLYMER BASED ON METHACRYLATES
The present invention relates to a premix comprising vemurafenib choline or vemurafenib as free form and cationic copolymer based on methacrylates and to oral dosage forms comprising said premix. Further, the invention relates to a process for producing said premix comprising vemurafenib choline or vemurafenib as free form and cationic copolymer based on methacrylates and to the corresponding process of producing an oral dosage form containing the premix of the invention.
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
The present invention is in the field devices for assisting in the provision of rehydration therapy in third world countries. It has been identified that rehydration therapy in third world is being administered using contaminated water thus causing a cycle of disease and ill-health. In order to address this is issue a device for dispensing a composition is provided according to the present invention. The device includes a first chamber; and a second chamber located adjacent to the first chamber. Each of the first and second chambers has an outlet. The first and second chambers are separated by a first filter and the first chamber contains a first composition and the second chamber contains a second composition.
A61J 7/00 - Devices for administering medicines orally, e.g. spoonsPill counting devicesArrangements for time indication or reminder for taking medicine
The present invention relates to a composition comprising cebranopadol in dissolved form and oral dosage forms comprising said composition. The invention further relates to a process for producing the composition comprising cebranopadol in dissolved form and to the corresponding process of producing an oral dosage form containing the composition of the invention.
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
The present invention relates to the tricyclic carbamoylpyridone Dolutegravir sodium 1,2-propylene glycol solvate, solid state forms thereof, processes for their preparation and pharmaceutical compositions containing Dolutegravir sodium 1,2-propylene glycol solvate.
A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
30.
COMPOSITION COMPRISING IVABRADINE IN A DISSOLVED FORM
The present invention relates to a composition comprising ivabradine in a dissolved form and oral dosage forms comprising said composition. The invention further relates to a process for producing the composition comprising ivabradine in a dissolved form and to the corresponding process of producing an oral dosage form containing the composition of the invention. Further, the invention relates to a method for treating cardiac diseases, preferably angina pectoris, comprising administering said composition. Finally, the invention relates to the use of a saturated ivabradine solution for the preparation of a solid oral dosage form.
The present invention relates to salts of idelalisib, polymorphs of these salts, methods for their preparation, and pharmaceutical preparations comprising these salts.
The present invention is in the field devices for assisting in the provision of rehydration therapy in third world countries. It has been identified that rehydration therapy in third world is being administered using contaminated water thus causing a cycle of disease and ill-health. In order to address this is issue a device for dispensing a composition is provided according to the present invention. The device includes a chamber containing a composition, the chamber having first and second outlets, a filter associated with the first outlet and a membrane associated with the second outlet.
The invention essentially relates to a pharmaceutical composition comprising an agglomerate of odanacatib and a releaser modifying polymer and further excipient, and a process of preparing such a pharmaceutical composition.
The present invention relates to acid addition salts of ibrutinib, a pharmaceutical composition comprising the same as well as a method of preparing the same.
Provided herein are solid state forms of Ruxolitinib besylate, processes for preparing the solid state forms, as well as pharmaceutical compositions and formulations comprising said solid state forms.
Provided herein are solid state forms of Ruxolitinib oxalate, processes for preparing the solid state forms, as well as pharmaceutical compositions and formulations comprising said solid state forms.
Provided herein are solid state forms of Vemurafenib hydrochloride, processes for preparing the solid state forms, as well as pharmaceutical compositions and formulations comprising said solid state forms.
C07D 401/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
TEVA PHARMACEUTICALS INTERNATIONAL GMBH (Switzerland)
RATIOPHARM GMBH (Germany)
Inventor
Stefan, Ralph
Mika, Hans-Juergen
Schenk, Dirk
Lauer, Claudia
Hrakovsky, Julia
Safonov, Roman
Chaurasia, Brijnath P.
Kansal, Vinod Kumar
Kumar, Pavan V.
Prajapati, Ramkaran
Srivastav, Naveen C.
Tripathi, Ashish
Muppalla, Siva Rama Krishna
Aronhime, Judith
Ratkaj, Marina
Abstract
The present invention relates to a pharmaceutical composition containing the active ingredient sofosbuvir. The composition, preferably in the form of a tablet, contains a high relative amount of active ingredient of 35 to 75 %. The patent also relates to the use of such a composition for the treatment of hepatitis C virus infections and to a process for preparing sofosbuvir tablets with such high drug load.
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
The present invention relates to prodrugs of monomethyl fumarate (MMF) of formula (I) suitable as a medicament, preferably in the treatment and/or prevention of systemic diseases, autoimmune diseases, inflammatory diseases, for example multiple sclerosis, rheumatoid arthritis and psoriasis. In formula (I) R is hydrogen and n is an integer from 1 to 10, or R is trans -CO-CH=CH-COOCH3 and n is an integer from 2 to 10, or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, and/or mixtures thereof.
A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
The present invention relates to novel compounds, e.g.for use as a medicament. In particular,the present invention relates to novel prodrugs of monomethyl fumarate (MMF) suitable as a medicament, preferably in the treatment and/or prevention of systemic diseases, autoimmune diseases, inflammatory diseases, for example multiple sclerosis and psoriasis.
C07C 229/22 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
The present invention relates to a pharmaceutical composition comprising trametinib or a pharmaceutically acceptable salt thereof as active ingredient and a carrier. The invention further relates to an intermediate for the preparation of said pharmaceutical composition and a method of preparing said pharmaceutical composition or said intermediate.
C07H 19/10 - Pyrimidine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids
A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
The present invention relates to Vemurafenib choline salt, solid state forms thereof, processes for preparation thereof and formulations thereof. The present invention also relates to the use of the solid state forms of Vemurafenib choline salt for preparing Vemurafenib or other Vemurafenib salts, and solid state forms thereof. Vemurafenib has the following chemical structure:
C07C 215/40 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
The present invention relates to novel compounds, e.g. for use as a medicament. In particular, the present invention relates to novel medicaments, preferably in the treatment and/or prevention of systemic diseases, autoimmune diseases, or inflammatory diseases, for example multiple sclerosis and psoriasis.
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 295/03 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
The present invention relates to fumarate esters, e.g. for use as a medicament. In particular, the present invention relates to novel medicaments, preferably in the treatment and/or prevention of systemic diseases, autoimmune diseases, and/or inflammatory diseases, for example multiple sclerosis and psoriasis.
C07C 69/67 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
C07C 219/08 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to an acyclic carbon atom of an acyclic unsaturated carbon skeleton
The present invention relates to novel compounds for use as a medicament. In particular, the present invention relates to a medicament, preferably in the treatment and/or prevention of systemic diseases, autoimmune diseases, inflammatory diseases, for example multiple sclerosis and psoriasis.
A61K 31/223 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-amino acids
A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
A61K 31/54 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
55.
MEDICAMENT COMPRISING A PHARMACEUTICAL COMBINATION OF DOLUTEGRAVIR, EMTRICITABINE AND TENOFOVIR
The present invention concerns a pharmaceutical combination comprising (a) dolutegravir, (b) emtricitabine and (c) tenofovir or a prodrug thereof, wherein preferably the compounds are present in a specific weight ratio and/or in specific amounts, for use as a medicament, preferably in treatment of viral infection/disease such as an HIV infection. Further, the present invention relates to a pharmaceutical composition comprising the pharmaceutical combination and optionally further pharmaceutical excipient(s).
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
The present invention relates to dosage forms comprising enzalutamide, wherein the enzalutamide is present in a dissolved form. Further, the invention relates to the use of a solvent having a specific HLB -value for producing a water/oil emulsion of an API having water- solubility of 1·10-3mg/ml to 1·10-2 mg/ml.
The present invention relates to a composition comprising tapentadol in a dissolved form and oral dosage forms comprising said composition. The invention further relates to a process for producing the composition comprising tapentadol in a dissolved form and to the corresponding process of producing an oral dosage form containing the composition of the invention. Finally, the invention relates to the use of a saturated tapentadol solution for the preparation of a solid oral dosage form.
Dolutegravir potassium salt and solid state forms thereof are provided, as well as methods of making and interconverting these forms. The Dolutegravir potassium forms, and pharmaceutical compositions containing them, may be used to treat subjects in need of medical treatment, such as for HIV infection.
A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
The present invention relates to a method for producing a dosage form, preferably a dosage form for immediate release, containing odanacatib wherein the method comprises the granulation with a specific granulation fluid. The invention further relates to a dosage form obtained according to said method.
The present invention relates to a solid pharmaceutical dosage from comprising ticagrelor and ASA as pharmaceutically active agents, to a package for storing the solid pharmaceutical dosage form and to a solid pharmaceutical dosage form for the use in the treatment of certain diseases.
Provided herein are solid state forms of Vemurafenib hydrochloride, processes for preparing the solid state forms, as well as pharmaceutical compositions and formulations comprising said solid state forms.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
The invention relates to a method of preparing a tablet, preferably a tablet for immediate release and having a high drug load, containing crizotinib in form of the free base and lubricant, both in specific amounts. The invention further relates to a tablet obtainable by said method.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
The present invention relates to a solid pharmaceutical dosage form comprising dolutegravir, a method of its preparation and its use in the treatment of an HIV infection.
A61K 31/535 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
The present invention relates to novel compounds for use as a medicament. In particular, the present invention relates to novel prodrugs of monomethyl fumarate (MMF) suitable as a medicament, preferably in the treatment and/or prevention of systemic diseases, autoimmune diseases, inflammatory diseases, for example multiple sclerosis and psoriasis.
A61K 31/223 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-amino acids
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/54 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
The invention relates to film coated pellets comprising an active ingredient having a high solubility in water. The invention also relates to methods of preparing said pellets and to cores comprising the active ingredient having a high solubility in water and to pharmaceutical compositions comprising the film coated pellets.
The present invention relates to a method for the production and purification of a sialyltransferase polypeptide, in particular a N-Acetylgalactosamine (Gal NAc)-α-2,6-sialyltransferase I (ST6GalNAcI) polypeptide. The method comprises the steps of producing the sialyltransferase polypeptide in a Chinese Hamster Ovary (CHO) cell and purifying the polypeptide with a combination of chromatography steps. The method results in high yield of sialyltransferase polypeptide which is highly pure and active. The obtained sialyltransferase, especially ST6GalNAcI, can be employed for the glycosylation of therapeutic proteins such as G-CSF.
Afatinib salts and crystalline forms thereof are described in the present application and processes for their preparation. Crystalline forms of Afatinib are also described in the present application and processes for their preparation. The present invention also includes pharmaceutical compositions of such Afatinib salts and crystalline forms thereof or crystalline forms of Afatinib, methods of their preparation and the use thereof in the treatment of a patient in need thereof.
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
69.
PHARMACEUTICAL FORMULATION COMPRISING TAPENTADOL AND CYCLODEXTRIN
The present invention relates to a pharmaceutical formulation comprising tapentadol and cyclodextrin. The invention further relates to a process for producing said pharmaceutical formulations. Finally, the invention relates to the use of cyclodextrin for producing a tapentadol-containing pharmaceutical formulation, wherein the pharmaceutical formulation has a dissolution of at least 0% after 15 min.
The present invention relates to complexes comprising aleglitazar and complexing agent. The invention further relates to a process for producing said complexes. Finally, the invention relates to the use of a pharmaceutical formulation comprising a PPAR modulator and cyclodextrin for the treatment of diabetes.
The present invention relates to amorphous aleglitazar, preferably together with a surface stabiliser in the form of a stable composition. The invention further relates to methods of preparing stable amorphous aleglitazar, and dosage forms containing stable amorphous aleglitazar. Finally, the invention relates to the use of a dosage form comprising an amorphous PPAR modulator for the treatment of diabetes.
The present invention relates to micronized aleglitazar, preferably in the form of a composition together with a hydrophilizing agent. The invention further relates to a method of preparing dosage forms containing micronized aleglitazar.
The invention essentially relates to oral dosage forms comprising a JAK kinase inhibitor, preferably Ruxolitinib, suitable for modified release, and processes of preparing such oral dosage forms.
The present invention relates to a complex of agomelatine and cyclodextrin, a composition comprising said complex, a process of preparing said complex and a pharmaceutical formulation comprising said complex or composition.
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
The present invention relates to Vemurafenib choline salt, solid state forms thereof, processes for preparation thereof and formulations thereof. The present invention also relates to the use of the solid state forms of Vemurafenib choline salt for preparing Vemurafenib or other Vemurafenib salts, and solid state forms thereof. Vemurafenib has the following chemical structure:
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
The invention relates to substantially pure Desfesoterodine salts, Desfesoterodine salts, solid state forms thereof and pharmaceutical compositions comprising one or more of the Desfesoterodine salts and/or solid state forms thereof.
C07C 215/54 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
The present invention provides salts of Crizotinib, solid state forms thereof, and pharmaceutical compositions comprising at least one of the salts or solid state forms. The invention includes crystalline forms of Crizotinib hydrochloride salt.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
The present invention provides solid state forms of Aleglitazar sodium, processes for preparing the solid state forms, and pharmaceutical compositions comprising the solid state forms.
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
79.
DOSAGE FORMS COMPRISING APIXABAN AND MATRIX FORMER
The invention relates to oral dosage forms for modified release of apixaban. The invention also relates to methods of preparing said dosage forms and to an agglomerated mixture of matrix former and filler for preparing an oral dosage form for use in the treatment of venous thromboembolism.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
The present invention relates to an oral dosage form comprising non-crystalline lopinavir and crystalline ritonavir. The invention further relates to methods of preparing said oral dosage forms containing the above pharmaceutical active agents.
The present invention relates to an oral dosage form comprising crystalline lopinavir and crystalline ritonavir. The invention further relates to methods of preparing said oral dosage forms containing the above pharmaceutical active agents.
The present invention is directed to several Tofacitinib salts including Tofacitinib mono-tartrate salt, Tofacitinib mono-malate salt and Tofacitinib mono-oxalate salt. These Tofacitinib salts can be in amorphous form. The invention is also directed toward a pharmaceutical composition comprising one or more of the Tofacitinib salts, and a process for preparing the composition. The Tofacitinib salts can be used to prepare Tofacitinib mono-citrate salt. Another aspect of the invention is a process for preparing Tofacitinib mono-citrate. The Tofacitinib salts of the invention are also useful as medicaments and in methods of treating patients suffering from cancer.
C07C 233/18 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
Crystalline forms of Afatinib di-maleate are described in the present application and processes for their preparation. The present invention also includes pharmaceutical compositions of such crystalline forms of Afatinib di-maleate, methods of their preparation and the use thereof hi the treatment of a patient in need thereof. The present invention also describes preparing Afatinib free base and salts of Afatinib, other than Afatibin di-maleate, and solid forms thereof.
C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
The invention relates to compositions and dosage forms containing edoxaban and a C02-forming agent, preferably for immediate release. Further the invention relates to the method for preparing said dosage forms and their use in the treatment of thrombotic diseases.
The present invention relates to a pharmaceutical composition having a density of more than 1.55g/cm3 in the form a tablet comprising 4-[4-[[4-chloro-3-(tifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridin e-2-carboxamide or a pharmaceutically acceptable salt thereof as active agent and at least one pharmaceutically acceptable excipient as well as a method of manufacturing such pharmaceutical composition.
The present invention concerns paiiperidone oleate, a solid state form thereof, pharmaceutical compositions comprising paiiperidone oleate, the use of paiiperidone oleate for the treatment of schizophrenia, and processes for preparing paiiperidone oleate and a solid state form of paiiperidone oleate. Formula(I)
The present invention relates to pharmaceutical compositions comprising dapagliflozin and cyclodextrin, preferably (2-hydroxy)propyl-β-cyclodextrin or γ-cyclodextrin, preferably as inclusion complex. The invention further relates to a process for producing said pharmaceutical compositions. Finally, the invention relates to the use of cyclodextrin for producing dapagliflozin-containing dosage forms and to methods of purification of dapagliflozin.
A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
90.
OPHTHALMIC PREPARATION COMPRISING A PGF2ALPHA ANALOGUE
The present invention relates to an aqueous ophthalmic preparation comprising a PGF2a analogue and at least one polyvinyl alcohol and the use thereof for the treatment of glaucoma and ocular hypertension.
The invention essentially relates to a pharmaceutical composition comprising ranolazine and hypromellose-acetate-succinate, suitable for modified release, and a process of preparing such a pharmaceutical composition.
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
The present invention relates to solid, non-crystalline agomelatine, a composition comprising said solid, non-crystalline agomelatine, a pharmaceutical formulation comprising said solid, non-crystalline agomelatine or said composition and methods for the preparation of said composition and formulation.
C07C 235/78 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61P 25/00 - Drugs for disorders of the nervous system
The present invention is directed to Tofacitinib acid addition salts and solid state forms thereof, particularl amorphons tofacitinib acetate, y as well as pharmaceutical compositions comprising one or more of them. The present invention further provides a process for producing Tofacitinib acid addition salt, in particular, Tofacitinib mono citrate salt.
Afatinib salts and crystalline forms thereof are described in the present application and processes for their preparation. Crystalline forms of Afatinib are also described in the present application and processes for their preparation. The present invention also includes pharmaceutical compositions of such Afatinib salts and crystalline forms thereof or crystalline forms of Afatinib, methods of their preparation and the use thereof in the treatment of a patient in need thereof.
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
The invention essentially relates to oral dosage forms comprising a JAK3 inhibitor, preferably tasocitinib, suitable for modified release, and processes of preparing such oral dosage forms.
The invention relates to pharmaceutical compositions, preferably tablets, comprising tasocitinib, suitable for immediate release, and processes of preparing such compositions.
The present invention relates to prasugrel or a pharmaceutically compatible salt thereof, compositions that contain this active substance and pharmaceutical compositions that contain this active substance or a composition containing this active substance. The present invention further relates to methods for producing the novel compositions.
A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
98.
TRANSDERMAL THERAPEUTIC SYSTEM (TTS) COMPRISING ROTIGOTINE
The present invention relates to a patch which comprises the active ingredient rotigotine and is intended for transdermal delivery of the active pharmaceutical ingredient rotigotine, comprising a backing layer (1), a matrix layer (2) which comprises the active ingredient, and a removable protective sheet (4) which is intended for removal before the patch is applied to the skin, characterized in that disposed with areal coverage between the matrix layer (2) and the removable protective sheet (4) is an additional interlayer (3).
The present invention provides ionic liquids of rotigotine, pharmaceutical compositions comprising said ionic liquids and methods of preparing such ionic liquids. The invention further provides methods of using the compositions described herein to overcome problems arising from polymorphism, solubility and delivery, to control release rates, to add functionality, to enhance efficacy, and to improve ease of use and manufacture.
The present invention provides arylsulfonate salts of Fingolimod, their solid state forms and pharmaceutical formulations comprising them. The present invention further provides arylsulfonate salts of Fingolimod for use in the treatment of multiple sclerosis. The invention includes arylsulfonate salts of Fingolimod and solid state forms described herein for use in the preparation of Fingolimod base or other salts of Fingolimod, solid state forms of these other salts, and pharmaceutical formulation comprising them. The present invention further provides a pharmaceutical composition comprising one or more of the Fingolimod arylsulfonate salts and solid state forms of the present invention.
C07C 215/28 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
C07C 309/29 - Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
C07C 309/30 - Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
